News Center

• Sep. 19

  2022

  CSPC Selected as One of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022”

  Recently, renowned pharmaceutical media “Healthcare Executive” published the list of “Top 100 Chinese Pharmaceutical Innovative Enterprises 2022". CSPC is once again among the first tier of the list.

• Sep. 13

  2022

  “TG103 INJECTION” OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

  “TG103 Injection”, a class 1 biological innovative drug of the Group, has been granted approval by the National Medical Products Administration of the PRC to conduct clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) in China.

• Sep. 13

  2022

  “TG103 INJECTION” OBTAINS CLINICAL TRIAL APPROVAL FOR THE TREATMENT OF ALZHEIMER’S DISEASE

  “TG103 Injection”, a class 1 biological innovative drug of the Group, has been granted approval by the National Medical Products Administration of the PRC to conduct clinical trials for the treatment of Alzheimer’s disease (AD) in China.

• Sep. 05

  2022

  CSPC Again Ranked in Brand Finance China 500

  “Brand Finance China 500 2022" was released. CSPC has been included in the list for the second time.

• Aug. 30

  2022

  “MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION” OBTAINS DRUG REGISTRATION APPROVAL

  The“Moxifloxacin Hydrochloride and Sodium Chloride Injection has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

• Aug. 30

  2022

  CLASS 1 NEW DRUG “PRUSOGLIPTIN TABLETS” MEETS PREDEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIALS

  The class 1 new drug “Prusogliptin Tablets” (“DBPR108 Tablets”) of CSPC has met the predefined endpoints in two pivotal clinical trials for the treatment of type 2 diabetes.